Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia

被引：0
|
作者：
Vanover, Kimberly [1 ]
Correll, Christoph [1 ]
Weingart, Michal [1 ]
Saillard, Jelena [1 ]
Hossain, Shawn [1 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Satlin, Andrew [1 ]
Davis, Robert [1 ]
机构：
[1] Intracellular Therapies Inc, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Schizophrenia Novel Treatment; Long-Term Safety; Antipsychotic;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T184
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [21] Effect of lumateperone (iti-007) on quality of life and functional disability in the treatment of bipolar depression
    Edwards, John
    Durgam, Suresh
    Kozauer, Susan G.
    Jain, Rakesh
    McIntyre, Roger S.
    BIPOLAR DISORDERS, 2022, 24 : 64 - 64
  • [22] ITI-007: A NOVEL THERAPY FOR THE TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES
    Vanover, Kimberly E.
    Snyder, Gretchen L.
    Hendrick, Joseph P.
    Fienberg, Allen A.
    Wennogle, Lawrence P.
    Mates, Sharon
    Davis, Robert E.
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 504 - 504
  • [23] Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomised clinical trial
    Yatham, L.
    Durgam, S.
    Kozauer, S.
    Chen, R.
    Davis, R.
    Mates, S.
    Tohen, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S308 - S309
  • [24] Safety and tolerability profile of lumateperone (ITI-007): Results from a phase 3 clinical trial for the treatment of bipolar depression
    Yatham, Lakshmi
    Durgam, Suresh
    Satlin, Andrew
    Vanover, Kimberly E.
    Davis, Robert E.
    Kozauer, Susan G.
    Huo, Jason
    Mates, Sharon
    BIPOLAR DISORDERS, 2020, 22 : 83 - 83
  • [25] ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
    Davis, Robert E.
    Correll, Christoph U.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (06) : 601 - 614
  • [26] The clinical development of lumateperone (ITI-007) for the treatment of bipolar depression: scientific rationale and clinical design
    Davis, R.
    O'gorman, C.
    Mates, S.
    Vanover, K.
    BIPOLAR DISORDERS, 2017, 19 : 61 - 61
  • [27] Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized clinical trial
    Yatham, Lakshmi
    Durgam, Suresh
    Kozauer, Susan G.
    Chen, Richard
    Davis, Robert E.
    Mates, Sharon
    Tohen, Mauricio
    BIPOLAR DISORDERS, 2021, 23 : 71 - 71
  • [28] Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia
    Correll, C. U.
    Vanover, K. E.
    Durgam, S.
    Weingart, M.
    Davis, R.
    Satlin, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S455 - S456
  • [29] Activation of NMDA and AMPA receptors by lumateperone (ITI-007): implications for antidepressant activity
    Snyder, G.
    Mates, S.
    Vanover, K.
    Dutheil, S.
    Hendrick, J.
    Wennogle, L.
    O'Gorman, C.
    Davis, R.
    Svensson, T.
    BIPOLAR DISORDERS, 2017, 19 : 127 - 127
  • [30] Phase 2 Evaluation of ITI-007, a Novel Approach to the Treatment of Schizophrenia
    Vanover, Kimberly E.
    Mates, Sharon
    Greengard, Paul
    Davis, Robert E.
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S386 - S387
12345